Table 4

Efficacy in the test population determined on the basis of gene status
All wild-type (N= 49) KRAS codon 12, 13 mutations (N= 21) KRAS codon 61, codon 146, BRAF, NRAS or PIK3CA mutations (any other mutations) (N= 12)
Complete response 1 0 0
Partial response 18 1 0
Stable disease 19 11 4
Progressive disease 11 9 8
Total 49 21 12
Response rate (%) 38.8 4.8 0 P = 0.006* (All wild-type vs. Any other mutations)
Disease control rate (%) 77.6 57.1 33.3 P = 0.006* (All wild-type vs. Any other mutations)
Progression-free survival [Median (95% CI) (months)] 6.1 (3.1, 9.2) 2.7 (1.2, 4.2) 1.6 (1.5, 1.7) P < 0.0001** (All wild-type vs. Any other mutations)
Overall survival [Median (95% CI) (months)] 13.8 (9.2, 18.4) 8.2 (5.7, 10.7) 6.3 (1.3, 11.3) P < 0.0001** (All wild-type vs. Any other mutations)
Relative dose intensity
Irinotecan [Median (range) (%)] 72.8 (13.0–100) 81.0 (38.4–100) 98.0 (49.3–100) P = 0.108***
Cetuximab [Median (range) (%)] 86.0 (35.7–100) 86.3 (11.1–100) 100 (80.0–100) P = 0.042***
Number of treatment cycles [Median (range)] 12 (1–86) 5 (1–23) 3 (1–12) P < 0.0001***

*: Fisher’s exact test.

**: log rank test.

***: Kruskal–Wallis test.

Bando et al.

Bando et al. BMC Cancer 2013 13:405   doi:10.1186/1471-2407-13-405

Open Data